Literature DB >> 28576632

The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents.

Edison S Zuniga1, Aaron Korkegian1, Steven Mullen1, Erik J Hembre2, Paul L Ornstein3, Guillermo Cortez2, Kallolmay Biswas4, Naresh Kumar4, Jeffrey Cramer2, Thierry Masquelin2, Philip A Hipskind2, Joshua Odingo1, Tanya Parish5.   

Abstract

We identified a di-substituted triazolopyrimidine with anti-tubercular activity against Mycobacterium tuberculosis. Three segments of the scaffold were examined rationally to establish a structure-activity relationship with the goal of improving potency and maintaining good physicochemical properties. A number of compounds displayed sub-micromolar activity against Mycobacterium tuberculosis with no cytotoxicity against eukaryotic cells. Non-substituted aromatic rings at C5 and a two-carbon chain connecting a terminal aromatic at C7 were preferred features; the presence of NH at C7 and a lack of substituent at C2 were essential for potency. We identified compounds with acceptable metabolic stability in rodent and human liver microsomes. Our findings suggest that the easily-synthesized triazolopyrimidines are a promising class of potent anti-tubercular agents and warrant further investigation in our search for new drugs to fight tuberculosis.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Anti-tubercular activity; Mycobacterium tuberculosis; Triazolopyrimidines; Tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28576632      PMCID: PMC5513444          DOI: 10.1016/j.bmc.2017.05.030

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  13 in total

1.  Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition.

Authors:  Nan Zhang; Semiramis Ayral-Kaloustian; Thai Nguyen; Jay Afragola; Richard Hernandez; Judy Lucas; James Gibbons; Carl Beyer
Journal:  J Med Chem       Date:  2007-01-25       Impact factor: 7.446

2.  Triazolopyrimidine compounds containing first-row transition metals and their activity against the neglected infectious Chagas disease and leishmaniasis.

Authors:  Ana B Caballero; Antonio Rodríguez-Diéguez; Miguel Quirós; Juan M Salas; Óscar Huertas; Inmaculada Ramírez-Macías; Francisco Olmo; Clotilde Marín; Guillermo Chaves-Lemaur; Ramón Gutierrez-Sánchez; Manuel Sánchez-Moreno
Journal:  Eur J Med Chem       Date:  2014-08-10       Impact factor: 6.514

3.  Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.

Authors:  Jose M Coteron; María Marco; Jorge Esquivias; Xiaoyi Deng; Karen L White; John White; Maria Koltun; Farah El Mazouni; Sreekanth Kokkonda; Kasiram Katneni; Ravi Bhamidipati; David M Shackleford; Iñigo Angulo-Barturen; Santiago B Ferrer; María Belén Jiménez-Díaz; Francisco-Javier Gamo; Elizabeth J Goldsmith; William N Charman; Ian Bathurst; David Floyd; David Matthews; Jeremy N Burrows; Pradipsinh K Rathod; Susan A Charman; Margaret A Phillips
Journal:  J Med Chem       Date:  2011-07-14       Impact factor: 7.446

4.  Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.

Authors:  Garrett C Moraski; Lowell D Markley; Philip A Hipskind; Helena Boshoff; Sanghyun Cho; Scott G Franzblau; Marvin J Miller
Journal:  ACS Med Chem Lett       Date:  2011-06-09       Impact factor: 4.345

5.  Essramycin: a first triazolopyrimidine antibiotic isolated from nature.

Authors:  Mervat M A El-Gendy; Mohamed Shaaban; Khaled A Shaaban; Ahmed M El-Bondkly; Hartmut Laatsch
Journal:  J Antibiot (Tokyo)       Date:  2008-03       Impact factor: 2.649

6.  Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization.

Authors:  Candice Soares de Melo; Soares de Melo Candice; Tzu-Shean Feng; Renier van der Westhuyzen; Richard K Gessner; Leslie J Street; Garreth L Morgans; Digby F Warner; Atica Moosa; Krupa Naran; Nina Lawrence; Helena I M Boshoff; Clifton E Barry; C John Harris; Richard Gordon; Kelly Chibale
Journal:  Bioorg Med Chem       Date:  2015-10-22       Impact factor: 3.641

7.  Discovery of triazolopyrimidine-based PDE8B inhibitors: exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes.

Authors:  Michael P DeNinno; Stephen W Wright; John B Etienne; Thanh V Olson; Benjamin N Rocke; Jeffrey W Corbett; Daniel W Kung; Kenneth J DiRico; Kim M Andrews; Michele L Millham; Janice C Parker; William Esler; Maria van Volkenburg; David D Boyer; Karen L Houseknecht; Shawn D Doran
Journal:  Bioorg Med Chem Lett       Date:  2012-07-06       Impact factor: 2.823

8.  A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.

Authors:  Juliane Ollinger; Mai Ann Bailey; Garrett C Moraski; Allen Casey; Stephanie Florio; Torey Alling; Marvin J Miller; Tanya Parish
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

9.  Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.

Authors:  Lluís Ballell; Robert H Bates; Rob J Young; Daniel Alvarez-Gomez; Emilio Alvarez-Ruiz; Vanessa Barroso; Delia Blanco; Benigno Crespo; Jaime Escribano; Rubén González; Sonia Lozano; Sophie Huss; Angel Santos-Villarejo; José Julio Martín-Plaza; Alfonso Mendoza; María José Rebollo-Lopez; Modesto Remuiñan-Blanco; José Luis Lavandera; Esther Pérez-Herran; Francisco Javier Gamo-Benito; José Francisco García-Bustos; David Barros; Julia P Castro; Nicholas Cammack
Journal:  ChemMedChem       Date:  2013-01-10       Impact factor: 3.466

10.  Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB.

Authors:  Katherine A Abrahams; Jonathan A G Cox; Vickey L Spivey; Nicholas J Loman; Mark J Pallen; Chrystala Constantinidou; Raquel Fernández; Carlos Alemparte; Modesto J Remuiñán; David Barros; Lluis Ballell; Gurdyal S Besra
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

View more
  11 in total

1.  Integrated Target-Based and Phenotypic Screening Approaches for the Identification of Anti-Tubercular Agents That Bind to the Mycobacterial Adenylating Enzyme MbtA.

Authors:  Lindsay Ferguson; Geoff Wells; Sanjib Bhakta; James Johnson; Junitta Guzman; Tanya Parish; Robin A Prentice; Federico Brucoli
Journal:  ChemMedChem       Date:  2019-09-23       Impact factor: 3.466

Review 2.  1,2,4-Triazolo[1,5-a]pyrimidines in drug design.

Authors:  Killian Oukoloff; Bobby Lucero; Karol R Francisco; Kurt R Brunden; Carlo Ballatore
Journal:  Eur J Med Chem       Date:  2019-01-14       Impact factor: 6.514

3.  Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis.

Authors:  Catherine Shelton; Matthew McNeil; Renee Allen; Lindsay Flint; Dara Russell; Bryan Berube; Aaron Korkegian; Yulia Ovechkina; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2022-03-09       Impact factor: 5.191

4.  Synthesis of 3-(5-amino-1H-1,2,4-triazol-3-yl)propanamides and their tautomerism.

Authors:  Felicia Phei Lin Lim; Lin Yuing Tan; Edward R T Tiekink; Anton V Dolzhenko
Journal:  RSC Adv       Date:  2018-06-19       Impact factor: 3.361

5.  Synthesis of Compounds of the Pyrimidine Series Based on the Reactions of 3-Arylmethylidenefuran-2(3H)-ones with N,N-Binucleophilic Reagents.

Authors:  Tatyana Aniskova; Vyacheslav Grinev; Alevtina Yegorova
Journal:  Molecules       Date:  2017-07-28       Impact factor: 4.411

6.  Anthranilic amide and imidazobenzothiadiazole compounds disrupt Mycobacterium tuberculosis membrane potential.

Authors:  Jake Smith; Heather Wescott; Julie Early; Steven Mullen; Junitta Guzman; Joshua Odingo; Jason Lamar; Tanya Parish
Journal:  Medchemcomm       Date:  2019-05-03       Impact factor: 3.597

7.  Retracted Article: The synthesis and biological activity of marine alkaloid derivatives and analogues.

Authors:  Shiyang Zhou; Gangliang Huang
Journal:  RSC Adv       Date:  2020-08-28       Impact factor: 4.036

8.  Novel camphor-based pyrimidine derivatives induced cancer cell death through a ROS-mediated mitochondrial apoptosis pathway.

Authors:  Yan Zhang; Yunyun Wang; Yuxun Zhao; Wen Gu; Yongqiang Zhu; Shifa Wang
Journal:  RSC Adv       Date:  2019-09-19       Impact factor: 4.036

9.  Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.

Authors:  Theresa O'Malley; Torey Alling; Julie V Early; Heather A Wescott; Anuradha Kumar; Garrett C Moraski; Marvin J Miller; Thierry Masquelin; Philip A Hipskind; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 10.  An insight on medicinal attributes of 1,2,4-triazoles.

Authors:  Ranjana Aggarwal; Garima Sumran
Journal:  Eur J Med Chem       Date:  2020-07-27       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.